Peter Welford analyst JEFFERIES

Currently out of the existing stock ratings of Peter Welford, 30 are a BUY (55.56%), 17 are a HOLD (31.48%), 7 are a SELL (12.96%).

Peter Welford

Work Performance Price Targets & Ratings Chart

Analyst Peter Welford, currently employed at JEFFERIES, carries an average stock price target met ratio of 57.22% that have a potential upside of 28.08% achieved within 371 days.

Peter Welford’s has documented 92 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GSK, GlaxoSmithKline PLC ADR at 12-Nov-2024.

Wall Street Analyst Peter Welford

Analyst best performing recommendations are on NVO (NOVO NORDISK A/S).
The best stock recommendation documented was for NVO (NOVO NORDISK A/S) at 8/30/2019. The price target of $22.26 was fulfilled within 14 days with a profit of $1.15 (4.91%) receiving and performance score of 3.51.

Average potential price target upside

AZN AstraZeneca PLC ADR GSK GlaxoSmithKline PLC ADR PLX Protalix Biotherapeutics CGEN Compugen GLPG Galapagos NV ADR GMAB Genmab AS NVO Novo Nordisk A/S NVS Novartis AG ADR SNY Sanofi ADR RHHBY Roche Holding Ltd ADR

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

19 days ago
(16-Oct-2025)

1/11 (9.09%)

$83.68 (135.40%)

2598

Buy

$87

$4.6 (5.58%)

$78

11 months 17 days ago
(18-Nov-2024)

8/9 (88.89%)

$24.91 (40.12%)

639

Buy

$88

$5.6 (6.80%)

$82

11 months 22 days ago
(13-Nov-2024)

4/5 (80%)

$24.05 (37.61%)

315

Buy

$95

$12.6 (15.29%)

$66

1 years 2 months 23 days ago
(12-Aug-2024)

6/7 (85.71%)

$14.17 (17.53%)

501

Buy

$85

$2.6 (3.16%)

$80

1 years 5 months 5 days ago
(30-May-2024)

4/4 (100%)

$10.26 (13.73%)

414

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Peter Welford?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?